reversed-phase chromatography raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-10 and is reviewed periodically as new material appears.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
The hot water supply hose of the umbilical is commonly 1⁄2 inch (13 mm) bore, and is connected to a supply manifold at the right hip of the suit with a set of valves which allow the diver to control flow to the front and back of the torso, and to the arms and legs, and to dump the supply to the environment if the water is too hot or too cold. The manifold distributes the water through the suit through perforated tubes. The hot-water suit is normally a one-piece neoprene wetsuit, fairly loose fitting, to fit over a neoprene undersuit, which can protect the diver from scalding if the temperature control system fails, with a zipper on the front of the torso and on the lower part of each leg. Gloves and boots are worn which receive hot water from the ends of the arm and leg hoses. If a full-face mask is worn, the hood may be supplied by a tube at the neck of the suit. Helmets do not require heating. The heating water flows out at the neck and cuffs of the suit through the overlap with gloves, boots, or hood.
== Investigation == Cell-matrix adhesions have been more extensively investigated by proteomics compared with cell-cell adhesions because they are more readily isolated from cells attached to glass. The advent of proximity biotinylation by birA* has facilitated the first proteomics-based studies of the cadherin adhesome.
She demands the removal of the Combine from Earth, but the G-Man says this would not be in the interests of his "employers". He instead shows her a vision taking place five years in the future, and offers her the chance to change the outcome of Eli's death at the hands of a Combine Advisor at the White Forest rocket facility. Alyx complies, killing the Advisor and saving her father. The G-Man informs Alyx that she has proven herself capable of replacing Freeman, with whom he has grown dissatisfied. Despite Alyx's protests, he suspends her in stasis and leaves. Five years later, Freeman regains consciousness at White Forest and is reunited with Eli. Realizing that the G-Man has Alyx, Eli declares his intention to kill him and hands Freeman his crowbar.
=== Psychiatric disorders === Valproate products are used to treat manic or mixed episodes of bipolar disorder. A 2016 systematic review compared the efficacy of valproate as an add-on for people with schizophrenia:
LiveNation (which already operates music venues at the site) will revamp the Budweiser Stage Amphitheatre into an indoor/outdoor facility with a capacity of up to 20,000 people in the summer and nearly 9,000 in winter. Austrian company Therme Group will develop the west island. A new large facility will cover most of the island. The facility will include indoor and outdoor pools, a spa, waterslides, restaurants, and a botanical garden. Outside of the facility, it will build a 12 acres (4.9 ha) public park and beach. The projected admission price for indoor activities is about $40 per person for full-day admittance. A third company proposed to build a zip-line and adventure park but pulled out of the project. The company and the government could not come to terms on the lease. Private sector investments are expected to be about $500 million. Public sector investment was not disclosed. A review process for environmental, heritage, and public consultation will likely extend into 2023. Construction is scheduled to begin in 2024, with a 2030 completion. In February 2022, Toronto city council voted to adopt a process to create an approvals process for the Province's plan for the redevelopment of Ontario Place. This process generally follows the city's traditional development approvals process, notwithstanding Ontario Place is predominately constructed on Provincially-owned land. Based on this timeline, a rezoning application is expected in late 2022 and a site plan approval process began in 2023. The Cinesphere was closed for renovations.
Sources: en.wikipedia.org
== Controversy == Doctor's Data has proven controversial because of the four lawsuits that have been filed by people who say that the company victimized them by diagnosing them as having toxic metal poisoning based on their urinalysis tests, and then prescribing them chelation therapy. According to Patricia Callahan, the problem with these tests and the way they are interpreted is that, after administering a chelator to their patients, "Doctor's Data...compared those drug-provoked results to a reference range calculated for people who had never been given a chelation drug." In addition, they have faced considerable criticism from Stephen Barrett, who has described how provoked urine test reports are used to mislead patients. and has also written negatively about hair analysis in general, which he contends is "unscientific, economically wasteful, and probably illegal." Arthur Allen has also criticized the methodology of their urinalysis tests, saying that they "...present the results [from their urine analysis tests] in such a way that it almost guarantees a finding of "toxicity" for each child." In response to this criticism, Doctor's Data president Ted Lueken argued that "the technique can be valuable when used along with other tests and a doctor's knowledge of his patient." Doctor's Data later sued Barrett on June 18, 2010, accusing him of "...harm[ing] Doctor's Data by transmitting false, fraudulent and defamatory information about this company in a variety of ways" in his writings about the company.
== Increasing stability of peptide drugs == Many strategies have been employed to increase the stability of peptide drugs, because although they have so many desirable characteristics, they are short lived in the body as a result of rapid degradation and clearance. With half-lives of some peptides and proteins only being a few minutes, they are very ineffective in drug delivery. Mechanisms involved in their clearance include peripheral blood mediated elimination by proteolysis, renal and hepatic elimination, and also receptor-mediated endocytosis. One of the main reasons for such rapid clearance is molecular weight. Molecules that have a low molecular weight (40-50 kDa) are rapidly cleared by renal filtration via the glomerular filtration barrier (GBM) into the urine. As a result of this, increasing the size of a peptide drug is a good starting point to improve half-life. Peptide modifications to extend half-life include PEGylation, glycosylation, cyclization, serum albumin binding, and lipidation. PEGylation is the attachment of polyethylene glycol (PEG) chains to the peptide via covalent bonds, helping to increase molecular weight, and limit enzymatic degradation as a result of steric hindrance caused by adding the PEG. PEGylation offers a number of benefits for pharmaceutical applications such as improved water solubility, high mobility in solution, as well as low toxicity and low immunogenicity. This does however depend on the molecular weight of the attached PEG.
=== Calcification and lipids === Calcification forms among vascular smooth muscle cells of the surrounding muscular layer, specifically in the muscle cells adjacent to atheromas and on the surface of atheroma plaques and tissue. In time, as cells die, this leads to extracellular calcium deposits between the muscular wall and outer portion of the atheromatous plaques. With the atheromatous plaque interfering with the regulation of calcium deposition, it accumulates and crystallizes. A similar form of intramural calcification, presenting the picture of an early phase of arteriosclerosis, appears to be induced by many drugs with an antiproliferative mechanism of action (Rainer Liedtke 2008). Cholesterol is delivered into the vessel wall by cholesterol-containing low-density lipoprotein (LDL) particles. To attract and stimulate macrophages, the cholesterol must be released from the LDL particles and oxidized, a key step in the ongoing inflammatory process. The process is worsened if there is insufficient high-density lipoprotein (HDL), the lipoprotein particle that removes cholesterol from tissues and carries it back to the liver. The foam cells and platelets encourage the migration and proliferation of smooth muscle cells, which in turn ingest lipids, become replaced by collagen, and transform into foam cells themselves. A protective fibrous cap normally forms between the fatty deposits and the artery lining (the intima). These capped fatty deposits (now called 'atheromas') produce enzymes that cause the artery to enlarge over time.
== Distribution and habitat == Species in the family Conidae are found in the tropical and subtropical seas of the world, in four biogeographic regions, including: the Indo-Pacific (with 60% of all species), the Tropical Eastern Pacific, the western Tropical Atlantic, and the eastern Tropical Atlantic, plus 10 species in the warm temperate Agulhas bioregion on the southern coast of South Africa. Fewer than one percent of fossil species have been found in more than one of the above regions. Cone snails are typically found in warm tropical seas and oceans worldwide. Cone snails reach their greatest diversity in the Western Indo-Pacific region. While the majority of cone snails are found in warm tropical waters, some species have adapted to temperate/semi-tropical environments and are endemic to areas such as the Cape coast of South Africa, the Mediterranean, or the cool subtropical waters of southern California (Californiconus californicus). They live on a variety of substrates, from the intertidal zone and deeper areas, to sand, rocks or coral reefs.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.